VAXCYTE INC. - COMMON STOCK

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

24 Oct 2022 06:30:00 By Nasdaq GlobeNewswire

Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults

23 Oct 2022 17:00:00 By Nasdaq GlobeNewswire

Vaxcyte Expands Executive Leadership Team with Key Appointments

11 Oct 2022 16:05:00 By Nasdaq GlobeNewswire

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

06 Sep 2022 16:04:00 By Nasdaq GlobeNewswire

Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update

08 Aug 2022 16:15:00 By Nasdaq GlobeNewswire

Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

04 Aug 2022 08:30:01 By Nasdaq GlobeNewswire

Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults

12 Jul 2022 16:05:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at the Jefferies Healthcare Conference

02 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update

09 May 2022 16:10:00 By Nasdaq GlobeNewswire

Vaxcyte to Participate in Upcoming Investor Conferences in May

03 May 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference

05 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults

04 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

28 Feb 2022 16:10:00 By Nasdaq GlobeNewswire

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

23 Feb 2022 16:05:01 By Nasdaq GlobeNewswire

Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

17 Feb 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference

10 Feb 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxcyte Announces Pricing of $100 Million Public Offering

13 Jan 2022 01:07:31 By Nasdaq GlobeNewswire

Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

12 Jan 2022 16:10:00 By Nasdaq GlobeNewswire

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

06 Jan 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at Upcoming Investor Conferences

11 Nov 2021 16:05:01 By Nasdaq GlobeNewswire